Abstract

Background: The FDA-approved drugs for female sexual interest, desire and/or arousal disorder (FSIAD), and hypoactive sexual desire disorder (HSDD); however, these drugs have low tolerability for patients because of their multiple side effects and do not show actual therapeutic efficacy. Hypoactive Sexual Desire affects approximately 750.000.000 to 1.400.000.000 people worldwide.

Methods: In this paper, we analyze therapeutic candidates in clinical practice as well as the methodologies of clinicaltrials of possible therapeutic targets of different systems related to the disorder.

Results: Therefore, clinical trials of new drugs (benzodiazepines, amphetamines, testosterone, sildenafil, or new compound) to evaluate their efficacy in treating this disorder are necessary.

Keywords: Increases, sexual, interest, desire, arousal, new drugs, treatment.